A Study of LY2584702 in Participants With Advanced Cancer
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this trial is to determine a recommended Phase 2 dose of LY2584702 that
may be safely administered to participants with advanced/metastatic cancer.